[ET Net News Agency, 11 December 2018] Sino Biopharmaceutical Limited (01177) announced
that Parecoxib Sodium for injection (including two specifications of 20mg and 40mg), an
analgesic product developed by its subsidiary Nanjing Chia Tai Tianqing Pharmaceutical
Co., Ltd., has obtained approval for drug registration by the National Medical Products
Administration of the PRC.
Parecoxib Sodium is the world's first selective cyclooxygenase-2 inhibitor for both
intravenous and intramuscular injections. With its characteristics of rapid onset,
long-lasting analgesic effect, high level of safety and good tolerance, the drug is now
widely used to relieve short-term post-operative pain. (RC)